Meeting
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
Authors
Tomasz M. Beer
OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Tomasz M. Beer , Fred Saad , Cora N. Sternberg , Maha H. A. Hussain , Arijit Ganguli , Hemant Singh Bhadauria , Mok Oh , Konstantina Skaltsa , Bertrand Tombal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 101)
DOI
10.1200/JCO.2021.39.6_suppl.101
Abstract #
101
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).
First Author: Richard Gagnon
Poster
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).
First Author: Irbaz Bin Riaz
Poster
2022 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2020 ASCO Virtual Scientific Program
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
First Author: Shan Jiang